Clara Rodríguez Fernández, Author at Labiotech.eu - Page 47 of 61

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Prexton Therapeutics Series B Forbion 1

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Innate Pharma lirilumab leukemia failure

News and Trends 6 Feb 2017

French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial

Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […]

February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

MaaT Pharma Herve Affagard interview

Interview 6 Feb 2017

“We want to be the Worldwide Leader in Microbiota”

Biotech entrepreneur Hervé Affagard, CEO of MaaT Pharma, tells the story behind the success of his young microbiome company. Hervé Affagard is the CEO and co-founder of a company with an ambitious goal: become the global leader in treating the gut microbiota. Founded in 2014 and based in Lyon, MaaT pharma wants to employ fecal transplants to treat […]

February 6, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

shutterstock 560991298

News and Trends 1 Feb 2017

Young Belgian Biotech will tackle Fibrosis with a New Grant

Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 566011132

News and Trends 1 Feb 2017

Young German Immune Therapy Biotech expands its Series A Funding

Immunic Therapeutics has received an extra €4M that will be directed at speeding the development of treatments for Crohn’s disease and psoriasis. Immunic Therapeutics is a young company based in Munich’s biotech hub that develops immune therapies for chronic inflammatory diseases. Today, it announced a €4M investment from IBG, which increases its Series A financing to a […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 563454787

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 566775526

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 563776360

News and Trends 31 Jan 2017

Top 5 Biologicals from European Biopharma to Launch in 2017

A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 559302181

News and Trends 30 Jan 2017

Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University

A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 515999191

News and Trends 30 Jan 2017

The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy

UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 562105219

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Tate Modern turbine hall e1485444882806

More News! 28 Jan 2017

Microbes Control the Massive Turbine Hall at London’s Tate Modern

Philippe Parreno’s Anywhen, occupying the vast hall at Tate Modern, evolves over time in response to the control of tiny living beings. When you enter Tate Modern‘s vast Turbine Hall, you might see lights turning off and on and hear noises coming and going. Without an apparent pattern, sounds and light evolve while families take […]

January 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT